01/01/2011 - Role of transporters in bioavailability of nutraceuticals and in risk assessement of environmental toxicants
M. Jani, I. Makai, E. Kis, P. Szabó, T. Nagy, P. Krajcsi and A. Lespine J PHARM SCI, J Pharm Sci. 2011 Jan;100(1):94-7
Abstract
Ivermectin is an antiparasitic drug frequently administered to humans. It has a limited brain exposure that is attributed to the efflux activity of ABCB1/Abcb1. ABCG2/Abcg2 is also a major transporter present in most pharmacologically important barriers. However, interaction of ivermectin with Abcg2 shows species specificity and in many studies was confounded by the masking effect of ABCB1/Abcb1. In this study using cellular and membrane assays we show that ivermectin displays a high-affinity interaction with human ABCG2 with IC(50) values in the 1-1.5 µM range. This interaction may have implications in human ABCG2-mediated drug-drug interactions of ivermectin.
open_in_new Read the SourcePrevious: ATP-Binding Cassette B1 Transports Seliciclib (R-Roscovitine), a Cyclin-Dependent Kinase Inhibitor